We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Lundbeck Research USA, Inc. and BioFocus Sign Compound Management Agreement

News   Jan 26, 2011

 
Lundbeck Research USA, Inc. and BioFocus Sign Compound Management Agreement
 
 
 

RELATED ARTICLES

Triple-negative Breast Cancers Can Adopt Reversible State That is Resistant to Chemotherapy

News

Researchers have discovered that triple-negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on molecular pathways that protect the cells.

READ MORE

Hyperactive Form of IRAK4 Protein Fuels Cancerous Cells

News

An international team of scientists report on a long-overlooked part of a leukemic cell’s internal machinery called the spliceosome, where they found a hyperactive form of a protein called IRAK4 that sends cells on a cancer-causing frenzy.

READ MORE

Guarding Against Cancer

News

Researchers from the University of Dundee have shown that a drug previously used to treat Type II diabetes could potentially be used to protect against cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE